Menu

Locate a Mesothelioma Cancer Center Near You

  • Information on top cancer centers and doctors
  • Find the right fit for your situation
  • Financial information to help with treatment costs
Get Connected

Some mesothelioma clinical trials are currently recruiting patients. Mesothelioma patients not responding well to traditional treatments may enroll in a clinical trial to test new treatment options. Interested mesothelioma patients should speak to their doctor about enrolling in an active clinical trial. In order to participate, patients have to meet criteria specific to the study.


01. Actively Recruiting Clinical Trials

Clinical Trials Recruiting Mesothelioma Patients

Participating in a clinical trial allows those who have been diagnosed with a serious illness, such as mesothelioma, to contribute to medical research. Each clinical trial has unique criteria and guidelines that prospective participants must meet in order to be considered for inclusion in the study. Because there are both benefits and risks to participating in a clinical trial it is always best to discuss any interest you may have with your doctor.

02. List of Clinical Trials

List of Clinical Trials Recruiting Mesothelioma Patients

Provided below is a list of active mesothelioma clinical trials that are still recruiting and enrolling participants. Click on a link to learn more about each study and the criteria for participation.

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies


Conditions: Mesothelioma, Gastrointestinal Neoplasms, Carcinoma, Peritoneal Neoplasms, Appendiceal Neoplasms

Last Updated: September 1, 2021

Status: Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors


Conditions: Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Adenocarcinoma of Lung, Teratoma, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Choriocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Cystadenocarcinoma, Paraganglioma, Chordoma, Hemangiosarcoma, Fibromatosis, Aggressive, Adenocarcinoma, Mucinous, Trophoblastic Neoplasms, Nerve Sheath Neoplasms, Gestational Trophoblastic Disease, Neurofibrosarcoma, Thyroid Neoplasms, Fibroma, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Carcinoma, Acinar Cell, Adenocarcinoma, Papillary, Adenocarcinoma, Bronchiolo-Alveolar, Neoplasms, Unknown Primary, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Adenocarcinoma, Clear Cell

Last Updated: August 31, 2021

Status: Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Last Updated: August 31, 2021

Status: Recruiting

Locations: Boston, MA. Detroit, MI. Pittsburgh, PA. Houston, TX. Seattle, WA.

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: August 27, 2021

Status: Recruiting

Locations: La Jolla, CA. Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Boston, MA. Ann Arbor, MI. Saint Louis Park, MN. New York, NY. Cleveland, OH. Philadelphia, PA. Pittsburgh, PA. Nashville, TN. Houston, TX.

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining


Conditions: Esophageal Neoplasms, Mesothelioma, Neoplasms

Last Updated: August 25, 2021

Status: Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)


Conditions: Carcinoma, Neoplasms, Small Cell Lung Carcinoma, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Cholangiocarcinoma, Colorectal Neoplasms, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases

Last Updated: August 25, 2021

Status: Recruiting

Locations: Los Angeles, CA. Los Angeles, CA. Orlando, FL. Baltimore, MD. Rockville, MD. Boston, MA. Boston, MA. Boston, MA. New Brunswick, NJ. Houston, TX.

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers


Conditions: Neoplasm Metastasis

Last Updated: August 24, 2021

Status: Recruiting

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion


Conditions: Neoplasms

Last Updated: August 24, 2021

Status: Recruiting

Locations: Scottsdale, AZ. Duarte, CA. Indianapolis, IN. New York, NY. Oklahoma City, OK. Nashville, TN. Houston, TX. San Antonio, TX.

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: August 20, 2021

Status: Recruiting

Locations: Tampa, FL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Sleepy Hollow, NY. Uniondale, NY. Houston, TX.

A Study of CPI-0209 in Patients With Advanced Tumors


Conditions: Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Prostatic Neoplasms, Lymphoma, T-Cell, Prostatic Neoplasms, Castration-Resistant

Last Updated: August 17, 2021

Status: Recruiting

Locations: Atlanta, GA. Baltimore, MD. Boston, MA. Boston, MA. Grand Rapids, MI. Hackensack, NJ. Bronx, NY. New York, NY. Cincinnati, OH. San Antonio, TX. Charlottesville, VA. Seattle, WA.

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: August 17, 2021

Status: Recruiting

Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.

Cardiac MRI Biomarker Testing (GCC 1618)


Conditions: Mesothelioma, Thymus Neoplasms

Last Updated: August 16, 2021

Status: Recruiting

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei

Last Updated: August 16, 2021

Status: Recruiting

Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors


Conditions: Carcinoma, Breast Neoplasms, Melanoma, Carcinoma, Squamous Cell, Adenocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Adenocarcinoma of Lung, Thyroid Neoplasms, Esophageal Neoplasms, Cystadenocarcinoma, Carcinosarcoma, Urinary Bladder Neoplasms, Adenomyoepithelioma, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous

Last Updated: August 13, 2021

Status: Recruiting

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma


Conditions: Mesothelioma

Last Updated: August 11, 2021

Status: Recruiting

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53


Conditions: Neoplasms

Last Updated: August 11, 2021

Status: Recruiting

Locations: Los Angeles, CA. New York, NY. Houston, TX. San Antonio, TX. Fairfax, VA.

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)


Conditions: Neoplasms, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

Last Updated: August 10, 2021

Status: Recruiting

Locations: Gainesville, FL. Miami, FL. Orlando, FL.

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)


Conditions: Mesothelioma

Last Updated: August 9, 2021

Status: Recruiting

Intravenous Magnesium in Patients Receiving Cisplatin


Conditions: Mesothelioma

Last Updated: August 2, 2021

Status: Recruiting

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma


Conditions: Mesothelioma, Wilms Tumor

Last Updated: August 2, 2021

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors


Conditions: Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Thymoma, Thymus Neoplasms

Last Updated: July 31, 2021

Status: Recruiting

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors


Conditions: Neoplasms, Mesothelioma, Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms, Prostatic Neoplasms, Neoplasms, Squamous Cell

Last Updated: July 28, 2021

Status: Recruiting

Locations: Scottsdale, AZ. Santa Monica, CA. Norwich, CT. Boston, MA. Boston, MA. Boston, MA. Danvers, MA. Las Vegas, NV. Oklahoma City, OK. Oklahoma City, OK. Nashville, TN. Nashville, TN. Houston, TX. San Antonio, TX.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Esophageal Squamous Cell Carcinoma, Endometrial Neoplasms

Last Updated: July 27, 2021

Status: Recruiting

Locations: Hackensack, NJ. Greenville, SC.

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma


Conditions: Mesothelioma

Last Updated: July 26, 2021

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II


Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: July 23, 2021

Status: Recruiting

Rapid Autopsy and Procurement of Cancer Tissue


Conditions: Mesothelioma, Urogenital Neoplasms

Last Updated: July 22, 2021

Status: Recruiting

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies


Conditions: Carcinoma, Neoplasms, Mesothelioma, Colorectal Neoplasms, Pseudomyxoma Peritonei, Peritoneal Neoplasms

Last Updated: July 21, 2021

Status: Recruiting

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma


Conditions: Mesothelioma

Last Updated: July 21, 2021

Status: Recruiting

Locations: Tampa, FL. Baltimore, MD. Detroit, MI. Minneapolis, MN.

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma


Conditions: Mesothelioma

Last Updated: July 19, 2021

Status: Recruiting

The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Mesothelioma

Last Updated: July 19, 2021

Status: Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas


Conditions: Adenocarcinoma, Sarcoma, Mesothelioma, Sarcoma, Ewing, Chondrosarcoma

Last Updated: July 16, 2021

Status: Recruiting

Locations: Scottsdale, AZ. Duarte, CA. Los Angeles, CA. Santa Monica, CA. Aurora, CO. Atlanta, GA. Chicago, IL. Grand Rapids, MI. Houston, TX. San Antonio, TX.

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma


Conditions: Lung Neoplasms, Mesothelioma

Last Updated: July 8, 2021

Status: Recruiting

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: July 6, 2021

Status: Recruiting

Locations: Baltimore, MD. Baltimore, MD. Houston, TX.

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies


Conditions: Neoplasms, Neoplasm Metastasis

Last Updated: July 1, 2021

Status: Recruiting

Locations: Grand Rapids, MI. Houston, TX. San Antonio, TX.

CAR T Cells in Mesothelin Expressing Cancers


Conditions: Mesothelioma, Fallopian Tube Neoplasms, Adenocarcinoma of Lung

Last Updated: June 29, 2021

Status: Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer


Conditions: Carcinoma, Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Transitional Cell, Endometrial Neoplasms, Bile Duct Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Penile Neoplasms

Last Updated: June 29, 2021

Status: Recruiting

Locations: Sacramento, CA. Bethesda, MD. Bethesda, MD. Columbus, OH. Pittsburgh, PA. Madison, WI.

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Cholangiocarcinoma

Last Updated: June 28, 2021

Status: Recruiting

Locations: San Francisco, CA. Bethesda, MD. New York, NY. Philadelphia, PA. Nashville, TN. Houston, TX.

UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC


Conditions: Mesothelioma

Last Updated: June 17, 2021

Status: Recruiting

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma


Conditions: Mesothelioma

Last Updated: June 15, 2021

Status: Recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies


Conditions: Carcinoma, Glioblastoma, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck

Last Updated: June 10, 2021

Status: Recruiting

Locations: Grand Rapids, MI. San Antonio, TX.

APG-2449 in Patients With Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: June 9, 2021

Status: Recruiting

A Study of SGN-CD228A in Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: May 27, 2021

Status: Recruiting

Locations: Birmingham, AL. Los Angeles, CA. Chicago, IL. Winston-Salem, NC. Cleveland, OH. Portland, OR. Pittsburgh, PA. Sioux Falls, SD. Houston, TX. San Antonio, TX.

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: May 27, 2021

Status: Recruiting

Locations: Tampa, FL. Tampa, FL. Tampa, FL. Chicago, IL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. New York, NY. Uniondale, NY. Cleveland, OH. Columbus, OH. Houston, TX. Seattle, WA.

A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat


Conditions: Lymphoma, Neoplasms, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Hematologic Neoplasms, Sarcoma, Synovial, Rhabdoid Tumor, Carcinoma, Medullary

Last Updated: May 26, 2021

Status: Recruiting

Locations: Encinitas, CA. Los Angeles, CA. Chicago, IL. Grand Rapids, MI. Canton, OH. Cincinnati, OH. Dallas, TX.

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: May 26, 2021

Status: Recruiting

Locations: Buffalo, NY. Philadelphia, PA.

Olaparib in Patients With HRD Malignant Mesothelioma


Conditions: Mesothelioma

Last Updated: May 12, 2021

Status: Recruiting

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy


Conditions: Stomach Neoplasms, Esophageal Neoplasms, Mesothelioma, Gastrointestinal Stromal Tumors, Anus Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular, Gastrointestinal Neoplasms

Last Updated: May 12, 2021

Status: Recruiting

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: April 30, 2021

Status: Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours


Conditions: Mesothelioma

Last Updated: April 29, 2021

Status: Recruiting

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors


Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Breast Neoplasms, Lung Neoplasms, Carcinoma, Basal Cell, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Thymoma, Small Cell Lung Carcinoma, Anus Neoplasms, Vulvar Neoplasms

Last Updated: April 28, 2021

Status: Recruiting

Locations: Los Angeles, CA. Los Angeles, CA. San Diego, CA. San Francisco, CA. Atlanta, GA. Chicago, IL. Fairway, KS. Detroit, MI. New York, NY. New York, NY. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Houston, TX. Salt Lake City, UT. Charlottesville, VA. Seattle, WA.

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors


Conditions: Neoplasms, Melanoma, Mesothelioma, Skin Neoplasms, Lung Neoplasms, Bone Neoplasms, Genital Neoplasms, Female, Soft Tissue Neoplasms, Endocrine Gland Neoplasms, Pharyngeal Neoplasms, Mouth Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Genital Neoplasms, Male, Sarcoma, Thyroid Diseases, Recurrence

Last Updated: April 28, 2021

Status: Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations


Conditions: Mesothelioma

Last Updated: April 21, 2021

Status: Recruiting

Locations: Houston, TX. San Antonio, TX.

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Hepatocellular, Stomach Neoplasms, Uterine Cervical Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Anus Neoplasms, Thymus Neoplasms, Microsatellite Instability

Last Updated: April 20, 2021

Status: Recruiting

Locations: New Haven, CT. Houston, TX.

Short Neoadjuvant Hemithoracic IMRT for MPM


Conditions: Mesothelioma

Last Updated: April 11, 2021

Status: Recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma


Conditions: Mesothelioma

Last Updated: April 9, 2021

Status: Recruiting

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: April 9, 2021

Status: Recruiting

A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma


Conditions: Mesothelioma

Last Updated: April 6, 2021

Status: Recruiting

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: April 6, 2021

Status: Recruiting

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin


Conditions: Mesothelioma, Pleural Diseases

Last Updated: March 30, 2021

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY.

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers


Conditions: Carcinoma, Merkel Cell, Mesothelioma, Neuroendocrine Tumors, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Microsatellite Instability

Last Updated: March 28, 2021

Status: Recruiting

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers


Conditions: Mesothelioma

Last Updated: March 21, 2021

Status: Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers


Conditions: Carcinoma, Merkel Cell, Lymphoma, Carcinoma, Endometrial Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell

Last Updated: March 15, 2021

Status: Recruiting

Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma


Conditions: Lymphoma, Carcinoma, Prostatic Neoplasms, Melanoma, Carcinoma, Squamous Cell, Leukemia, Myeloid, Acute, Ovarian Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Stomach Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Adenoid Cystic, Thymoma, Lung Neoplasms

Last Updated: March 11, 2021

Status: Recruiting

Locations: Duarte, CA. Morristown, NJ. New York, NY. Houston, TX. Milwaukee, WI.

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S


Conditions: Neoplasm Metastasis, Brain Neoplasms, Astrocytoma, Mesothelioma, Cholangiocarcinoma, Esophageal Neoplasms, Thymoma, Tongue Neoplasms, Urologic Neoplasms

Last Updated: March 8, 2021

Status: Recruiting

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin


Conditions: Mesothelioma

Last Updated: March 8, 2021

Status: Recruiting

Locations: Phoenix, AZ. Los Angeles, CA. San Francisco, CA. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Rochester, MN. New York, NY. Houston, TX. Alessandria, Alabama. Milano, Michigan.

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome


Conditions: Carcinoma, Melanoma, Mesothelioma, Cholangiocarcinoma, Meningioma

Last Updated: March 7, 2021

Status: Recruiting

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM


Conditions: Mesothelioma

Last Updated: March 5, 2021

Status: Recruiting

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients


Conditions: Mesothelioma

Last Updated: March 2, 2021

Status: Recruiting

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: February 25, 2021

Status: Recruiting

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies


Conditions: Mesothelioma, Disease Progression

Last Updated: February 25, 2021

Status: Recruiting

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery


Conditions: Mesothelioma

Last Updated: February 17, 2021

Status: Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma


Conditions: Neoplasms, Mesothelioma, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Biliary Tract Neoplasms

Last Updated: February 11, 2021

Status: Recruiting

DENdritic Cell Immunotherapy for Mesothelioma


Conditions: Mesothelioma

Last Updated: January 26, 2021

Status: Recruiting

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: January 22, 2021

Status: Recruiting

First-in-human Study of S-588210 (S-488210+S-488211)


Conditions: Mesothelioma

Last Updated: January 22, 2021

Status: Recruiting

Autologous Dendritic Cell Vaccination in Mesothelioma


Conditions: Mesothelioma

Last Updated: January 15, 2021

Status: Recruiting

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases


Conditions: Neoplasms, Sarcoma, Mesothelioma, Lung Neoplasms, Esophageal Neoplasms, Neoplasms, Germ Cell and Embryonal, Thymus Neoplasms

Last Updated: January 9, 2021

Status: Recruiting

Phase I Trial HIPEC With Nal-irinotecan


Conditions: Mesothelioma, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Pseudomyxoma Peritonei

Last Updated: November 27, 2020

Status: Recruiting

Locations: Lexington, KY. Stony Brook, NY.

Integrated Cancer Repository for Cancer Research


Conditions: Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Salivary Gland Neoplasms, Anus Neoplasms, Gallbladder Neoplasms, Bile Duct Neoplasms, Oropharyngeal Neoplasms, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Urethral Neoplasms, Vaginal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms, Hereditary Nonpolyposis, Testicular Neoplasms, Intestinal Neoplasms, Hypopharyngeal Neoplasms, Penile Neoplasms, Ureteral Neoplasms, Neoplasms, Plasma Cell, Peritoneal Neoplasms, Paranasal Sinus Neoplasms, Duodenal Neoplasms, Neoplasms, Unknown Primary, Lip Neoplasms, Thymus Neoplasms, Paraproteinemias

Last Updated: November 10, 2020

Status: Recruiting

Locations: Colorado Springs, CO. Denver, CO. Durango, CO. Lakewood, CO. Littleton, CO. Longmont, CO. Louisville, CO. Parker, CO. Pueblo, CO. Westminster, CO. Daytona Beach, FL. DeLand, FL. Orange City, FL. Palm Coast, FL. Aurora, IL. Moline, IL. Yorkville, IL. Fort Wayne, IN. Indianapolis, IN. Indianapolis, IN. Indianapolis, IN. Kokomo, IN. Council Bluffs, IA. Davenport, IA. Spencer, IA. Waterloo, IA. Overland Park, KS. New Orleans, LA. Portland, ME. Randallstown, MD. Westminster, MD. Holyoke, MA. Ann Arbor, MI. Aitkin, MN. Brainerd, MN. Duluth, MN. Duluth, MN. Fergus Falls, MN. Marshall, MN. Joplin, MO. Kansas City, MO. Kansas City, MO. Kansas City, MO. Liberty, MO. Saint Joseph, MO. Kalispell, MT. Missoula, MT. Hastings, NE. Norfolk, NE. North Platte, NE. O'Neill, NE. Omaha, NE. Omaha, NE. Omaha, NE. Scottsbluff, NE. Glens Falls, NY. Utica, NY. Fayetteville, NC. Fargo, ND. Minot, ND. Pittsburgh, PA. Aberdeen, SD. Mitchell, SD. Sioux Falls, SD. Sioux Falls, SD. Yankton, SD. Yankton, SD. Yankton, SD. Rutland, VT. Fredericksburg, VA. Appleton, WI. Brookfield, WI. Franklin, WI. Mequon, WI. Milwaukee, WI. Oshkosh, WI. Racine, WI. Wauwatosa, WI.

eRAPID: Online Symptom Reporting in Lung Cancer


Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma

Last Updated: November 5, 2020

Status: Recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors


Conditions: Carcinoma, Breast Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck

Last Updated: October 22, 2020

Status: Recruiting

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma


Conditions: Mesothelioma

Last Updated: September 25, 2020

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms

Last Updated: September 15, 2020

Status: Recruiting

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural

Last Updated: September 10, 2020

Status: Recruiting

Dose Individualization of Pemetrexed - IMPROVE-II


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: September 10, 2020

Status: Recruiting

Staging Procedures to Diagnose Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural

Last Updated: September 10, 2020

Status: Recruiting

Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural

Last Updated: September 10, 2020

Status: Recruiting

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: September 9, 2020

Status: Recruiting

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: August 21, 2020

Status: Recruiting

Rehabilitation by Effort for Patients With Advanced Bronchial Cancer


Conditions: Mesothelioma, Carcinoma, Bronchogenic

Last Updated: July 29, 2020

Status: Recruiting

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: July 27, 2020

Status: Recruiting

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma


Conditions: Mesothelioma, Fever

Last Updated: July 14, 2020

Status: Recruiting

Dose Individualization of Pemetrexed - IMPROVE-I


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: July 10, 2020

Status: Recruiting

Dose Individualization of Pemetrexed - IMPROVE-III


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: July 10, 2020

Status: Recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: June 29, 2020

Status: Recruiting

HMPL-453 in Advanced Malignant Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: June 12, 2020

Status: Recruiting

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma


Conditions: Mesothelioma

Last Updated: June 11, 2020

Status: Recruiting

Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors


Conditions: Carcinoma, Neoplasms, Sarcoma, Glioblastoma, Mesothelioma, Neuroendocrine Tumors, Endometrial Neoplasms, Stomach Neoplasms

Last Updated: June 5, 2020

Status: Recruiting

Locations: Boston, MA.

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours


Conditions: Mesothelioma, Neuroendocrine Tumors, Thymoma

Last Updated: May 3, 2020

Status: Recruiting

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed


Conditions: Mesothelioma

Last Updated: December 13, 2019

Status: Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies


Conditions: Leukemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mesothelioma, Sarcoma, Synovial, Esophageal Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms

Last Updated: December 10, 2019

Status: Recruiting

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: December 2, 2019

Status: Recruiting

Mesothelioma and Radical Surgery 2


Conditions: Mesothelioma

Last Updated: October 28, 2019

Status: Recruiting

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)


Conditions: Mesothelioma, Pancreatic Neoplasms, Gallbladder Neoplasms, Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pleural Effusion, Ascites

Last Updated: October 7, 2019

Status: Recruiting

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: October 4, 2019

Status: Recruiting

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy


Conditions: Mesothelioma, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Uterine Neoplasms, Fever

Last Updated: April 15, 2019

Status: Recruiting

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Fever

Last Updated: October 15, 2018

Status: Recruiting

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)


Conditions: Mesothelioma, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Last Updated: March 16, 2018

Status: Recruiting

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung


Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Carcinoma, Neuroendocrine

Last Updated: November 18, 2016

Status: Recruiting

Get Help Contacting



    Privacy policy: All information is secure and will never be released

    TRUSTe